Loading
A single chromatogram can be forged. A single m/z can be misassigned. We require both to agree on every peptide we sign — plus the dose-accuracy markers (NPC, TFA), the GLP-1-specific impurity scan, and the endotoxin / sterility data injectable-grade buyers ask for.
Every assay a la carte, every panel bundled. Bulk discount at 5+ samples. Prices below reflect a single-compound submission.
HPLC purity %. The baseline every research peptide should carry.
HPLC purity + Identity + NPC + TFA. The complete peptide identity-and-dose receipt.
Identity + Potency + endotoxin (LAL) + microbial. Injection-grade documentation for clinical and research use.
HPLC purity + Identity + NPC + TFA on a named GLP-1. The complete identity-and-dose receipt for any Semaglutide, Tirzepatide, Retatrutide, or Cagrilintide lot.
Identity + endotoxin (LAL) + heavy metals + sterility. The complete safety package for compounding pharmacies and clinical-research buyers.
GLP-1 Identity at 5+ samples per submission. For compounding-pharmacy lot QC and continuous incoming-material verification.
Kinetic chromogenic LAL by USP <85> with inhibition / enhancement validation. Standard add-on for any injectable peptide.
Endotoxin + bioburden + heavy metals for injectable-grade peptides and APIs. The injection-safety package.
Formal USP <71> sterility test (14-day media incubation) plus LAL endotoxin. Required for terminally-sterilized injectable products.
Synthesis byproducts, counter-ion mismanagement, storage degradation, and process-water endotoxin account for most flagged peptide lots. Knowing where the risk concentrates is the first half of the testing scope.
Research peptide testing operates outside the FDA finished-drug regulatory loop, but USP and ICH standards still anchor the analytical methods. Here's what we map to.
USP <85> LAL methodology for endotoxin quantitation. Kinetic chromogenic on the Charles River Endosafe stack with documented inhibition / enhancement validation. Required for any peptide intended for injectable / parenteral use.
Direct inoculation or membrane filtration into fluid thioglycolate (anaerobic / facultative) and soybean-casein digest (aerobic / fungal) media. 14-day incubation. Required for terminally-sterilized injectable peptides and APIs.
Permitted Daily Exposure limits for Pb, Cd, As, Hg in pharmaceutical-grade material. Available as the heavy-metal impurity scan add-on or bundled into the GLP-1 Full Screen and Full Safety Panel.
ICH thresholds for reporting, identification, and qualification of impurities. Our HPLC method reports any impurity peak above 0.1 % area; impurities above 0.5 % get individual MS identification.
Instrument software audit trails, raw chromatograms, and mass spectra retained per 21 CFR Part 11-style data-integrity principles. Available to the client of record on request.
HPLC purity % is the fraction of the main peak among all peptide-containing material. NPC is the fraction of total dry mass that is actually peptide — the rest is TFA / acetate counter-ions, water, and salts. NPC is typically lower than purity %. Both matter for dose accuracy: a 10 mg vial at 99 % purity but 78 % NPC contains 7.8 mg of actual peptide.
Identity, residual solvents, USP <232> metals on the bulk material before it becomes a finished peptide.
Label-claim verification, ICP-MS heavy metals, microbial bioburden, banned-substance screen.
Active-ingredient potency for cosmetic peptides plus PET and MoCRA conformance.